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ABSTRACT The aim of this paper was to demonstrate the potential of the fuzzy system approach to the
analysis of healthcare databases for clinicians in their routine daily practice. The healthcare data about
50 000 medical prescription items for 38 990 individual patients and 2601 various codes of diagnoses
categorized according to Slovak version of the tenth revision of the International Statistical Classification
of Diseases and Related Health Problems were used for the retrospective study. The fuzzy system approach
was applied to the analysis of medical prescription items for I10.90 and E11.90 comorbid patients as the
most frequently identified cardiovascular and endocrine codes of diagnoses. Nearly 64% of co-identified
I10.90 and E11.90 patients were associated with other additional diagnose. According to the fuzzy system
approach, the metformin or glimepiride in combination with moxonidine, metoprolol, or amlodipine was
identified as the mainstream drug preferences and/or individual ‘‘know-how’’ of clinicians in pharmacother-
apy of mentioned polymorbid patients from 21 various active substances. The results of this paper suggest
that the fuzzy system approach to healthcare data obtained from insurance companies may be a helpful way
of generating information useful for final decision process in the drugs selection for similar polymorbid
patients in medical practice. The obtained data can be used as recommendations for other and/or for less
experienced clinicians in drugs selection for patients with similar (or unusual) combinations of diagnoses
as well as in clinical situations where the ‘‘golden’’ pharmacotherapeutic standards have not been precisely
specified or are totally absent for multi-comorbid patients.
INDEX TERMS Decision-making process, drugs delivery, fuzzy system, health information management,
patient monitoring.
I. INTRODUCTION
Effective pharmacotherapy is based on the drugs prescribed
in relevant medicinal products suitable for the patient’s cur-
rent diagnosis or a combination of diagnoses. The clini-
cal decision support software always involved some type
of up-to-date passive electronic drug reference database
based on data from drug handbooks, pocket cards, published
scientific papers or approved by ‘‘Summary of Product
Characteristics (SPC),’’ which described drug indica-
tions, contraindications, doses and interactions. However,
the above-mentioned sources used for drug databases do not
describe the diagnoses in a uniform manner according to
the International Statistical Classification of Diseases and
Related Health Problems (ICD).Moreover, the approved SPC
do not mention drug indications, which are not licensed but
are usually clinically be used as ‘‘off-label.’’ Besides, some
degree of variability may still exist between licensed indica-
tions or frequency of drugs side effects of medicinal products
produced by several pharmaceutical companies with regard
to the same active substance. In this case, the processing and
evaluation of drug data is more than problematic [1], [2].
On the other hand, the knowledge of individual clinicians
about clinical effects of applied drugs in everyday practice
reaches a statistical significance in time with the number of
drug (co-)applications to individual patients. Moreover, data
are generally statistically significant among the clinicians
because the numbers of treated patients and drug application
occurrences are high. Although these data are available in
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healthcare databases of insurance companies, they are not
systematically summarized in an available database, so it is
not possible to establish rules for any expert system. More-
over, the setting up of such a database is problematic also
for unrealistic way to ask each clinician for the reason why
she/he decided to apply a selected drug (or drug combination)
in a selected case. In the reference [3] two methods – Loewe
Additivity and Bliss Independence – are used to determine the
combination of drugs (Quantifying Synergistic Drug Com-
binations). The Loewe Additivity method needs informa-
tion about the concentration of inhibitors in the drug and it
investigates overall inhibition of the resulting combination.
Bliss Independence models statistically compute predicted
combined effects of drug A and B as a product of individual
effects with drugs A and B. Because the combination of
drugs gives enormous number of possible drug combinations,
strategies to reduce search space and prioritize experiments
are needed [ 4], [5].
In this case, the potential of fuzzy logic principles in which
the variables in the system are represented and manipulated
in a binary manner may be applied. The variables may be
defined in discrete termswhile the transition between discrete
terms can be gradual. A value for a variable might partially
belong to a set and have a degree of membership anywhere
between 0 and 1 and thus it can partially belong to several
sets with the total membership adding to one [6]. The fuzzy
system have the structure of a series of ‘‘if-then’’-rules to
form knowledge base and fuzzy rules present mathematical
relationships mapping inputs to outputs [6], [7]. Although the
fuzzy logic is not appropriate in all cases like in linear system
models or if there are large amounts of missing data [3], [6],
the several successful applications of the fuzzy principles in
medical practice [7]–[11] with special regard to pharmacol-
ogy have already been recently described [6], [9], [12]–[14].
The potential of the fuzzy system approach to the drug-
prescribing analysis according to the anatomical therapeutic
chemical (ATC) classification system among clinicians has
already been used but only in the analysis of their regional
prescribing patterns [15]. As mentioned in the literature [16],
the recommended systems based on fuzzy logic currently
present successful solutions to facilitate access for online
users to the information fitting their preferences. Collabo-
rative filtering systems can generate recommendations only
using users’ ratings and without any need for additional
information. Collaborative filtering focuses on suggesting to
the target user the items that are already preferred by other
users with similar preference patterns.
In contrast to this, the aim of this study was to demonstrate
the potential of the Sugeno fuzzy model based system which
for acquisition of information basically allows the use of
both implicit expert knowledge of physicians as well as of
a drug database obtained from the State Institute for Drug
Control in Slovakia for the Quantifying synergistic drug
combinations. The fuzzy approach to analysis of healthcare
databases represents a new tool for creating information that
is useful for final decision-making process of drug selection
for defined polymorbid group of patients in medical
practice.
II. METHODS
In the literature [17], two levels of classification (taxonomy)
for the fuzzy system software are proposed. The first level
represents the software developed according to the aim for
which it was developed – this is the purpose-based taxon-
omy. Standardized software by the type (library, toolbox, and
so on) presents the second level. In terms of this classification,
we can include the proposed first-level expert system into
the ‘‘Fuzzy Systems Software for Specific Application Pur-
poses’’ category, designed for Solving Specific Problems of
Pharmacy. From view of the second level, we can rank it into
the category ‘‘General-Purpose Fuzzy Systems Toolboxes,’’
namely the Sugeno fuzzy system.
The healthcare data about the total of 50,000 medical pre-
scription items for the retrospective study were obtained from
the second largest Slovak insurance company as cvs files and
they covered the period of 9 months (from December 2014 to
August 2015). The healthcare data in each row included a
seven-digit digital anonymous code of individual patient, its
gender and age. Besides, the code of the patient diagnoses,
categorized according to Slovak version of Tenth revision
of ICD (ICD-10-Sk) [18] was available. The individual pre-
scribed active substances according to the ATC classification
system and trade names of dispensed medicinal products
defined by State Institute for Drug Control codes were acces-
sible. The additional information covered dispensed quantity
of medicinal products, the date of dispensation and special-
izations of prescribed clinicians. The medical prescription
items were prescribed for the group of 38,990 individual
patients and 2,601 various ICD-10-Sk codes of diagnoses.
For the sake of clarity, the fuzzy system approach was applied
to the analysis of medical prescription items for polymorbid
patients with the most frequently identified cardiovascular
and endocrine ICD-10-Sk codes. The term of polymorbid
patients was used for patients with two or more verified
recorded diagnoses. In Slovakia, the health insurance is obli-
gated for all residents and is financed by means of social
contributions of employers, employees and the state. The res-
idents can freely choose from one state and two commercial
insurance companies that pay health care in the same amount
and scope.
The proposed fuzzy concept was based on the following
assumptions:
1) Experiences and knowledge of clinicians (‘‘know-
how’’) were expressed in their decisions for pre-
scription of drugs combination for a certain patient
diagnosis.
2) A quantitative relation exists between a certain combi-
nation of diagnoses and the suitability of a particular
drug application for its treatment.
3) With the concurrent application of two or more drugs
there was a relation between the suitability of combina-
tion of their diagnoses, and this relation quantitatively
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defines the suitability of application of their mutual
combination.
4) The more frequently a certain combinations of drugs
occurred in the prescriptions for a certain combination
of diagnoses, the more it was preferred for their treat-
ment by clinicians.
TABLE 1. Setting up of example of initial knowledge database from
healthcare data.
TABLE 2. Co-occurrence of drugs and diagnoses and their quantitative
expression in the range of < 0, 1 >.
Algorithm for the sequence of obtaining information on the
relations between drugs and diagnoses was based on:
1) Setting up a knowledge database for a specific
drug or diagnosis. Table 1 demonstrates the example
of initial database for 4 drugs (L1–L4), 3 diagnoses
(D1–D3) and 10 patients (P1–P10) where L4 drug was
prescribed 5 times, together with L1 drug that was pre-
scribed once, with L2 drug that was prescribed twice,
for diagnosis D2 which was prescribed four times, etc.
2) Modification of the knowledge database and determi-
nation of the universe (selecting only the diagnoses that
occur in sufficient quantity and within the defined time
interval) for the individual drug (diagnosis). Divid-
ing the co-occurrence of two drugs by the total num-
ber of occurrences (expressed diagonally in yellow
color in Table 2 of the drug (ratio against the diago-
nal) we obtain a value within the range of <0, 1>.
The zero (0) value means that the two drugs never
occur together, the one (1) value means they always
FIGURE 1. Graphic expression: (a) of mutual relation of drugs L2, L3, L4;
(b) fuzzy representation of drug L1.
occur together. This value can be understood as a
‘‘quantitative expression of the relation (distance)’’
between two drugs. Besides, for each drug there can
be defined the set of drugs (and diagnoses) with which
the drug had so far co-occurred. It is intuitively clear
that if drugs <L2, L3> are ‘‘close,’’ and at the same
time drugs <L2, L4> are ‘‘close’’ and at the same
time drugs <L3, L4> are ‘‘close,’’ then also drugs
<L2, L3, L4> will be mutually ‘‘close.’’
3) Compiling a distance table for co-administered drugs
(Table 2).
4) Determining the fuzzy relation between drugs and diag-
noses in the form of its fuzzy representation FIS (fuzzy
inference system) – the quantitative value of the fuzzy
relation depends on their mutual occurrence (Fig. 1).
The quantitative expression of the mutual closeness
of a triplet of drugs is a function of the closeness of the
individual pairs expressed as the area of the ‘‘S’’ trian-
gle (Fig. 1(a)). In general, the quantitative expression
of mutual closeness (i.e. of the suitability or relation
of mutual combination defined by clinicians) of an
n-tuple of drugs is their mutual relation in (n-1) dimen-
sional space (Fig. 1(b)) for the fuzzy representation of
drug L1.
It is rather a problem to determine this relation ana-
lytically as the set of drugs is not organized. It seems a
suitable tool for determining such relation consists in its
fuzzy representation, i.e. a mathematical description by
means of a set of fuzzy rules between its inputs and out-
puts. For example, for drug L1 its fuzzy representation
would be FIS (Fuzzy Inference System) L1 (and thus
the quantitative value of the relation S (L2, L3, L4))
expressed by seven rules from Table 2 in the form:
1. If L2 then S = 0.00,
2. If L3 then S = 0.25,
3. If L4 then S = 0.25,
4. If L2 and L3 then S = 0.23,
5. If L2 and L4 then S = 0.15,
6. If L3 and L4 then S = 0.21
7. If not L2 and not L3 and not L4 then S = 0.
and its fuzzy Sugeno type representation would
be in the form as shown in Fig. 2.
For the drug combination [L1 L3] (which is expressed
in the representation by the entry combination L2 = 0,
L3 = 1, L4 = 0) the representation yields suitability
of application of 0.25, which is precisely in line with
Table 2.
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FIGURE 2. Fuzzy representation of drug L1 for combination with L3.
For the three-drug combination [L1 L2 L4] this repre-
sentation yields suitability of application 0.15, which is
also in line with Table 2, as illustrated in Fig. 3.
FIGURE 3. Fuzzy representation of drug L1 for three-drug combination
with L2 and L4.
By compiling a pre-processed ‘‘fuzzy representation’’
of each drug (diagnosis) in the form of Table 2, or the
fuzzy representation as in Fig. 2 and Fig. 3, one will
obtain a quantitative expression of its relations (rela-
tionships, number of applications, distances) with other
drugs and diagnoses.
Note: For the sake of clarity, the ‘‘sharp’’ (crisp) infor-
mation has been used at development of the fuzzy
system, and in this case the fuzzification result is the
same as in Table 2. Using fuzzy information, the result
would not be the same, but the designed fuzzy system
could handle it.
The fuzzy evaluation of combinations of drugs or diag-
noses was based on the:
1) Consolidation of universes for individual drugs, and
2) Fuzzy inference for a group of drugs and was per-
formed in MATLAB R© software (version 2016A).
III. RESULTS
Oracle Database SystemOracle Corporation, based on a stan-
dard PS of the type HP Z4 G4 with 16 GB DDR4 memory
and a 1 TB (7200 rpm) hard disk, was chosen for specific
implementation of the proposed expert system. The database
of input data about drugs, recipes, and patients collected
during one year period and having the size of 2.93 GB was
obtained from a health insurance company.
In the first stage of data processing, relevant interactions
between drugs and diagnoses were found using PL/SQL
language and based on these a fuzzy image of each drug in
the table form was created. Thus, approximately 4500 fuzzy
images (tables) of different sizes were obtained; these pre-
sented a fuzzy image database of individual drugs.
In the second phase a script was created which, based on
the given input combination of drugs and the database of
their fuzzy images, calculated the fuzzy image of the overall
mutual situation of the drugs (e.g., see Tab.2). This allows to
determine the weight of their mutual occurrence and thus the
suitability of their mutual prescription.
For the case study the database was reduced to
50,000 records, so it was possible to apply the Microsoft
Office Access2007 database engine to create fuzzy images
of the drugs and for processing of these images an m-file of
the MATLAB 2013b package was used.
The most frequent cardiovascular diagnosis identified
according to ICD-10-Sk was unspecified primary hyperten-
sion without hypertensive crisis (I10.90), present in 2.7 % of
all analyzed patients (Table 3).
TABLE 3. Analyzed subgroup of polymorbid patients by the fuzzy system
approach.
The most frequent endocrine diagnosis identified accord-
ing to ICD-10-Sk compensated Type 2 diabetesmellitus with-
out complications (E11.90), presented in 0.9% of all analyzed
patients. The group of patients with I10.90 diagnoses were
treated with overall 198 various active substances (Table 3).
On the other hand, the group of patients with E11.90 diag-
noses were treated only with 116 various active substances
(Table 3).
In the analyzed subgroup of polymorbid patients with
co-identified I10.90 and E11.90 diagnoses, the total of 21 var-
ious active substances were found (Table 3, Table 4).
Nearly 64 % of these patients were also associated with
other additional diagnosis (Table 3, Table 4). According to
the fuzzy system analysis for E11.90 and I10.90 polymorbid
patients, the most preferred prescription identified was that of
metformin or glimepiride in combination with moxonidine,
metoprolol or amlodipine (Table 4).
In more detail, the most frequent identified antidi-
abetic active substances for E11.90 patients with only
VOLUME 6, 2018 27297
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TABLE 4. The fuzzy analysis of prescribed active substances in E11.90 and I10.90 polymorbid patients.
I10.90 diagnoses were metformin and gliclazide (Table 4).
Moreover, metformin was also the most frequently identified
active substance in E11.9 and I10.90 patients with other
additional diagnosis (Table 4). On the other hand, meto-
prolol, amlodipine and moxonidine were the most frequent
identified antihypertensive active substances for E11.90 and
I10.90 patients (Table 4).
IV. DISCUSSION
In our experimental retrospective study in which the poten-
tial of the fuzzy system approach to analysis of healthcare
databases was used, the metformin or glimepiride (as antidi-
abetic drugs) in combination with the metoprolol, amlodip-
ine or moxonidine (as antihypertensive drugs) was identified
as the most appropriate for E11.90 and I10.90 comorbid
patients from the real health insurance database.
According to the international guidelines, the beta block-
ers (BB) or calcium channel blockers (CCB) belong to the
rationale drug class of choice in the treatment of hypertensive
diabetic patients [19], [20]. They are also recommended by
The Commission for Rational Pharmacotherapy and Drug
Policy of The Slovak Ministry of Health [21]. They are also
recommended by The Slovak Society of Cardiology [21].
Besides, the CCB and BBwere the second and third preferred
group of antihypertensive drugs after angiotensin-converting
enzyme inhibitors (ACEI) in everyday practice of questioned
general practice doctors in Slovakia in the treatment of
hypertensive patients [22] and were preferred groups of anti-
hypertensive monotherapy in primary care of hypertensive
diabetic patients [23]. Although the risk of major vascular
events was significantly reduced in ACEI treated hyperten-
sive patients with type 2 diabetes compared to amplodipine
ones [24], it seems, that the benefit of amplodipine prevents
early atherosclerotic lesions in mentioned patients as it was
demonstrated by decreasing the intimal-medial thickness of
the common carotid artery [25].
On the other hand, the blood pressure lowering effect
of amlodipine was comparable with the metabolically
also neutral ACEI in hypertensive patients with type
2 diabetes [24], [25].
The meta-analysis of randomized clinical trials revealed
that systolic and diastolic blood pressure lowering effect
of amlodipine monotherapy was also comparable with the
metoprolol monotherapy of hypertensive patients [26].
On the other hand, the data of the double-blind multi-
center randomized study with metoprolol and moxonidine
indicated effective comparable blood pressure control in
hypertensive patients with type 2 diabetes although the long-
term treatment with moxonidine seem to be more suit-
able for decrease of global vascular disease risk associated
with glucose and lipid metabolism [27]. In comparison to
metformin, the moxonidine was able to improve insulin
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utility in hypertensive patient with impaired glucose tolerance
although was not able to reduce HbA1C level [28]. In the
same groups of patients, the moxonidine as well as metformin
was able to improve significantly Matsuda insulin sensitivity
index, significantly reduced body mass index and normal-
ized blood pressure [28]. Although the metformin com-
pared to glimepiride did not significantly reduce important
metabolic risk factors of atherosclerotic vascular disease in
normotensive diabetic patients [29], the metformin seems to
be preferred therapy than sulfonylureas for diabetic patients
with cardiovascular comorbidities including hypertension for
significantly more effective reducing strokes [30], [31] and
non-fatal cardiovascular events [32].
As our results illustrated, the analysis of obtained health-
care databases by the fuzzy system approach can identify
mainstream drug preferences of clinicians and/or individual
experience (‘‘know-how’’) of clinicians in pharmacotherapy
of polymorbid patients with selected (defined) groups of
individual diagnoses. As we discussed above, the obtained
results must be always carefully verified. Moreover, the
elimination of inadequate data associated with real clinical
mistake decisions, which ones can be identified as frequent
(or rare) and may be (or not) recommended, must be con-
sidered. Only after this consideration the results can be used
as recommendations for other and/or for less experienced
clinicians in drugs selection for polymorbid patients with
similar (or unusual) combinations of diagnoses. In frequent
combinations of diagnoses, specific patient characteristics
and main clinical parameters of patients may be added to the
fuzzy system algorithms in the final drug decision-making
process. Moreover, the obtained data about the administered
drugs in selected diagnoses may be additionally or simul-
taneously be analyzed by computerized databases for elim-
ination of relative or absolute drug contraindications as well
as for elimination of serious and harmful drug-drug inter-
actions. Another advantage of the presented fuzzy system
approach to large healthcare databases can consists in drug
selection/recommendation for clinicians in clinical situations
where the ‘‘golden’’ pharmacotherapeutic standards have not
been precisely specified or are totally absent for individual
groups of multi-comorbid patients. For group of patients
with rarely combined diagnoses or in case of short time use
of recently registered drug in clinical practice, the obtained
suitability identified by the fuzzy system as low or zero must
be carefully interpreted. In this case, a follow up comment
may be added to the databases.
The expert systems based on crisp data do not allow
to simply combine information from experts with informa-
tion retrieved from the recipes database. Considering the
philosophy of the proposed system, it is not a matter of
principle to add information obtained from the State Insti-
tute for Drug Control to the fuzzy pictures of individual
drugs and diagnoses in the first step of the algorithm at its
compounding (where ‘‘1’’ is assigned for the recommended
diagnosis and ‘‘0’’ is assigned for a forbidden diagnosis
or drug).
Similarly, information from the manufacturer or expert can
be added to the fuzzy image of each individual drug or diag-
nosis by adding an appropriate rule (a relation) and a function
of relevance (quantitative relation rating) considering another
drug or diagnosis.
In case the information database would be built only on
crisp data, it is possible to achieve the same results using
other methods of processing. Because of the fact that the
information is always inserted into the database also in a
linguistic way (by producers, experts), the use of the fuzzy
system is justified by the fact that it can easily combine crisp
information with information containing uncertainties.
When processing more complex large-scale databases
(e.g. from health insurance companies), professional database
systems have to be employed for pre-processing of data
(creating fuzzy representations of particular database com-
ponents), which only needs to be carried out once over a
longer period of time, e.g. a year. The created fuzzy models
can then be easily implemented and used on standard PCs,
e.g. in pharmacies and in doctors’ offices.
V. CONCLUSION
The results of this study suggest that the fuzzy system
approach to obtained healthcare data from insurance compa-
nies may be a helpful way of generating information useful
for final decision-making in the drugs selection process for
similar polymorbid patients in medical practice.
The analysis of obtained healthcare databases by the fuzzy
system approach can identify mainstream drug preferences
of clinicians and/or individual experience (‘‘know-how’’) of
clinicians in pharmacotherapy of polymorbid patients with
selected (defined) groups of individual diagnoses.
The results can be used as recommendations for other
and/or for less experienced clinicians in drugs selection for
polymorbid patients with similar (or unusual) combinations
of diagnoses.
The advantage of the fuzzy system approach to large
healthcare databases can be drug selection/recommendation
for clinicians in clinical situations where the ‘‘golden’’
pharmacotherapeutic standards have not been precisely spec-
ified or are totally absent for individual groups of multi-
comorbid patients.
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